Valeant Pharma (VRX) Shares Look to Move Higher
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Mizuho Securities Upgrades Valeant Pharma (VRX) to Neutral on SOTP Valuation
August 15, 2016 6:07 AM EDTMizuho upgrades Valeant Pharma (NYSE: VRX) from Underperform to Neutral and moves its price target from $11 up to $25.
Analyst Irina R. Koffler commented today:
VRX outfoxes the shorts via financial engineering, in spite of a 2Q:16 miss: Valeant reported rev of $2.4B and $1.40 EPS vs. consensus estimates $2.47B and $1.47 and our estimates $2.51B and $1.54. Management reiterated its FY:16 guidance of $9.9-$10.1B in revenue and EPS range of $6.60-$7.00, which we still view as unrealistic given the 2.2% sequential... More